tradingkey.logo
tradingkey.logo
Pesquisar

Journey Medical Corp

DERM
Adicionar à lista de desejos
6.250USD
-0.080-1.26%
Fechamento 05/18, 16:00ETCotações atrasadas em 15 min
134.59MValor de mercado
PerdaP/L TTM

Mais detalhes de Journey Medical Corp Empresa

Journey Medical Corporation is a commercial-stage pharmaceutical company. The Company is focused on selling and marketing of the United States Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the United States. Its marketed products, which have been approved FDA for sale in the United States, include Qbrexza, Accutane, Amzeeq, Zilxi, Exelderm Cream and Solution, Targadox, and Luxamend. Qbrexza is a medicated cloth towelette for the treatment of primary axillary hyperhidrosis. Accutane is an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne. Targadox is an oral doxycycline drug for adjunctive therapy for severe acne. Luxamend is a water-based emulsion formulated to provide moist healing environment.

Informações de Journey Medical Corp

Código da empresaDERM
Nome da EmpresaJourney Medical Corp
Data de listagemNov 12, 2021
CEOMaraoui (Claude)
Número de funcionários41
Tipo de títulosOrdinary Share
Fim do ano fiscalNov 12
Endereço9237 E Via De Ventura Blvd., Suite 105
CidadeSCOTTSDALE
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal85258
Telefone14804346670
Sitehttps://journeymedicalcorp.com/
Código da empresaDERM
Data de listagemNov 12, 2021
CEOMaraoui (Claude)

Executivos da empresa Journey Medical Corp

Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Claude Maraoui
Mr. Claude Maraoui
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.29M
+10.02%
Mr. Ramsey Alloush
Mr. Ramsey Alloush
Chief Operating Officer, General Counsel
Chief Operating Officer, General Counsel
470.73K
+32.73%
Dr. Lindsay A. Rosenwald, M.D.
Dr. Lindsay A. Rosenwald, M.D.
Executive Chairman of the Board
Executive Chairman of the Board
330.44K
-14.36%
Mr. Joseph Benesch, CPA
Mr. Joseph Benesch, CPA
Chief Financial Officer, Corporate Controller
Chief Financial Officer, Corporate Controller
187.57K
+46.27%
Mr. Neil Herskowitz
Mr. Neil Herskowitz
Independent Director
Independent Director
81.44K
-21.42%
Ms. Miranda Jayne Toledano
Ms. Miranda Jayne Toledano
Independent Director
Independent Director
81.44K
-21.42%
Mr. Michael C. Pearce
Mr. Michael C. Pearce
Independent Director
Independent Director
10.00K
-471.73%
Mr. Justin Smith
Mr. Justin Smith
Independent Director
Independent Director
--
--
Ms. Jaclyn Jaffe
Ms. Jaclyn Jaffe
Investor Relations
Investor Relations
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Claude Maraoui
Mr. Claude Maraoui
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.29M
+10.02%
Mr. Ramsey Alloush
Mr. Ramsey Alloush
Chief Operating Officer, General Counsel
Chief Operating Officer, General Counsel
470.73K
+32.73%
Dr. Lindsay A. Rosenwald, M.D.
Dr. Lindsay A. Rosenwald, M.D.
Executive Chairman of the Board
Executive Chairman of the Board
330.44K
-14.36%
Mr. Joseph Benesch, CPA
Mr. Joseph Benesch, CPA
Chief Financial Officer, Corporate Controller
Chief Financial Officer, Corporate Controller
187.57K
+46.27%
Mr. Neil Herskowitz
Mr. Neil Herskowitz
Independent Director
Independent Director
81.44K
-21.42%
Ms. Miranda Jayne Toledano
Ms. Miranda Jayne Toledano
Independent Director
Independent Director
81.44K
-21.42%

Detalhamento da receita

Moeda: USDAtualizado em: seg, 6 de abr
Moeda: USDAtualizado em: seg, 6 de abr
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
Por EmpresaUSD
Nome
Receita
Proporção
Qbrexa
25.01M
40.85%
Emrosi
14.74M
24.08%
Accutane
12.88M
21.04%
Amzeeq
5.86M
9.57%
Other branded revenue
2.74M
4.47%
Por RegiãoUSD
Nome
Receita
Proporção
United States
61.86M
0.00%
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
Qbrexa
25.01M
40.85%
Emrosi
14.74M
24.08%
Accutane
12.88M
21.04%
Amzeeq
5.86M
9.57%
Other branded revenue
2.74M
4.47%

Distribuição de ações

Atualizado em: qua, 13 de mai
Atualizado em: qua, 13 de mai
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Fortress Biotech Inc
15.74%
Maraoui (Claude)
10.73%
Wasatch Global Investors Inc
9.99%
Tang Capital Management, LLC
8.69%
Vanguard Capital Management, LLC
5.07%
Outro
49.78%
Investidores
Investidores
Proporção
Fortress Biotech Inc
15.74%
Maraoui (Claude)
10.73%
Wasatch Global Investors Inc
9.99%
Tang Capital Management, LLC
8.69%
Vanguard Capital Management, LLC
5.07%
Outro
49.78%
Tipos de investidores
Investidores
Proporção
Hedge Fund
21.80%
Investment Advisor/Hedge Fund
17.26%
Individual Investor
16.85%
Investment Advisor
16.39%
Corporation
15.74%
Private Equity
2.08%
Insurance Company
0.88%
Research Firm
0.44%
Pension Fund
0.24%
Outro
8.31%

Participação acionária institucional

Atualizado em: qua, 1 de abr
Atualizado em: qua, 1 de abr
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2026Q1
137
12.08M
56.62%
+2.74M
2025Q4
111
6.92M
29.29%
--
2025Q3
113
6.92M
33.12%
+300.88K
2025Q2
111
6.62M
36.44%
+1.49M
2025Q1
80
5.12M
29.92%
+3.29K
2024Q4
74
3.80M
30.46%
+100.75K
2024Q3
75
2.18M
26.36%
-187.63K
2024Q2
70
2.37M
22.85%
+547.02K
2024Q1
61
1.83M
18.72%
-778.53K
2023Q4
59
1.36M
20.20%
-795.63K
Ver Mais

Atividade dos acionistas

Nome
Ações detidas
Proporção
Variação
Var. %
Data
Fortress Biotech Inc
3.36M
15.75%
--
--
Apr 14, 2025
Maraoui (Claude)
2.06M
9.66%
+1.24M
+150.79%
Aug 25, 2025
Wasatch Global Investors Inc
1.32M
6.17%
+10.00K
+0.77%
Dec 31, 2025
Tang Capital Management, LLC
1.85M
8.69%
--
--
Dec 31, 2025
Opaleye Management Inc.
975.00K
4.57%
+3.94K
+0.41%
Dec 31, 2025
J. Goldman & Co., L.P.
798.37K
3.74%
+798.37K
--
Dec 31, 2025
BlackRock Institutional Trust Company, N.A.
655.76K
3.07%
+83.84K
+14.66%
Dec 31, 2025
Alloush (Ramsey)
316.68K
1.48%
+46.86K
+17.37%
Jun 17, 2025
Millennium Management LLC
457.81K
2.15%
+457.81K
--
Dec 31, 2025
Ver Mais

ETFs Relacionados

Atualizado em: sáb, 6 de dez
Atualizado em: sáb, 6 de dez
Nome
Proporção
iShares Micro-Cap ETF
0.02%
iShares Russell 2000 Growth ETF
0.01%
Global X Russell 2000 ETF
0%
ProShares Hedge Replication ETF
0%
iShares Russell 2000 ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
Dimensional US Core Equity 1 ETF
0%
ProShares UltraPro Russell2000
0%
Royce Quant Small-Cap Quality Value ETF
0%
Proshares Ultra Russell 2000
0%
iShares Micro-Cap ETF
Proporção0.02%
iShares Russell 2000 Growth ETF
Proporção0.01%
Global X Russell 2000 ETF
Proporção0%
ProShares Hedge Replication ETF
Proporção0%
iShares Russell 2000 ETF
Proporção0%
DFA Dimensional US Sustainability Core 1 ETF
Proporção0%
Dimensional US Core Equity 1 ETF
Proporção0%
ProShares UltraPro Russell2000
Proporção0%
Royce Quant Small-Cap Quality Value ETF
Proporção0%
Proshares Ultra Russell 2000
Proporção0%

Dividendo

Um total de 0.00 USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados

Desdobramento de ações

Data
Data ex-dividendo
Tipo
Proporção
Sem dados
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
KeyAI